newsfilter
← Latest News
Business Wire·

Aldeyra Therapeutics Highlights Recent Preclinical Data in Obesity, Atopic Dermatitis, Pain, and Alcoholic Hepatitis, and Announces Planned Pivotal Clinical Trial in Retinitis Pigmentosa, at 2024 Research & Development Day

Live Webcast Scheduled to Begin at 9 am EDT Today Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) (Aldeyra) will host the Aldeyra 2024 Research & Development Day with investors and financial analysts in New York City to